查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949525

就業和職場藥物檢測市場－全球產業規模、佔有率、趨勢、機會和預測（按類型、產品、模式、藥物、最終用途、地區和競爭格局分類），2021-2031年

Employer And Workplace Drug Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product, By Mode, By Drug, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球雇主和職場藥物檢測市場預計將從 2025 年的 63.6 億美元成長到 2031 年的 84.1 億美元，複合年成長率為 4.77%。

此市場領域涵蓋用於篩檢員工非法藥物使用和藥物濫用的檢測服務和診斷產品。市場成長的根本驅動力在於高風險產業嚴格的政府安全法規，以及企業為最大限度降低與職場和生產力損失相關的責任而做出的努力。這些促進因素源自於核心營運風險管理和法律合規需求，而非採用新的檢測技術。

市場概覽
預測期 2027-2031
市場規模：2025年 63.6億美元
市場規模：2031年 84.1億美元
複合年成長率：2026-2031年 4.77%
成長最快的細分市場 運輸
最大的市場 北美洲

然而，日益複雜的與大麻相關的法律為市場擴張帶來了巨大障礙。州和聯邦法律的衝突使得雇主難以法規。這種監管碎片化阻礙了標準化檢測通訊協定的實施，並導致對降低後的績效標準的執行存在不確定性。根據美國卡車運輸協會（ATA）的數據，到2024年，大麻將佔商業駕駛員陽性藥物檢測結果的約60%，凸顯了企業在不斷變化的法律環境下維護安全通訊協定所面臨的巨大挑戰。

市場促進因素

嚴格的政府指令和監管要求，以及對職場安全的迫切需求，是全球雇主和職場藥物檢測市場的主要促進因素。在物流和製造業等高風險行業，法律要求雇主實施嚴格的篩檢措施，以預防事故並降低企業責任。持續存在的藥物相關安全事故威脅加劇了這種運作上的必要性。根據Quest Diagnostics於2025年9月發布的《2025年藥物檢測指數》，到2024年，美國工人事故後藥物檢測呈陽性的比例將達到10.2%，這凸顯了在安全事故發生後進行檢測以識別風險因素的重要性。這些強制性規定確保了穩定的市場需求基礎，使其能夠抵禦經濟波動。

同時，全球非法藥物濫用和鴉片類藥物成癮的流行正在推動市場發展，也使得更全面、更頻繁的篩檢通訊協定變得尤為重要。隨著全球藥物消費量的增加，員工接觸藥物的風險也隨之上升，迫使各組織實施徹底的檢測，以保障員工的生產力和健康。根據聯合國毒品犯罪防制署（UNODC）於2024年6月發布的《2024年世界毒品報告》，到2022年，全球非法藥物使用者人數將達到2.92億，比過去十年成長20%。職場的醫療緊急情況進一步凸顯了這個問題的嚴重性。根據美國國家安全委員會（NSC）2025年的數據，2024年，因職場可能發生的鴉片類藥物過量事件，緊急醫療服務出動次數超過12600次。

市場挑戰

日益複雜的與大麻相關的法律為全球雇主和職場藥物檢測市場的成長帶來了重大障礙。儘管越來越多的州已將醫用和娛樂用大麻合法化，但聯邦法律仍然禁止大麻，這使得雇主面臨著錯綜複雜的相互衝突的合規要求。這種監管碎片化顯著增加了在藥物影響下工作的法律責任和不確定性，尤其是在非監管職業中。因此，各組織機構變得更加規避風險，縮減篩檢程序或完全取消大麻檢測以避免訴訟風險。這直接導致檢測量減少，並限制了診斷服務的普及。

這種猶豫不決對市場的影響在近期行業數據中顯而易見，數據顯示，它限制了藥物檢測的全面普及。根據美國人力資源管理協會（SHRM）統計，截至2024年，只有40%的雇主表示將對受監管和不受監管的職業進行藥物檢測。這一數字表明，相當一部分企業仍在猶豫是否要實施全面的篩檢計畫。由於監管方面的混亂，無法建立標準化的檢測政策，這有效地限制了市場的目標基本客群，並抑制了收入成長。

市場趨勢

在運輸部核准和近期對吸食大麻檢測需求的推動下，基於實驗室的快速口腔液檢測正日益普及，並重塑著市場格局。此方法採用全程監控的非侵入式採集方式，降低了尿液檢查中常見的檢體竄改風險。在安全敏感領域，雇主越來越傾向於採用這種方法來區分過去的大麻史和當前的大麻影響，這在合法化地區至關重要。檢測量的顯著成長也印證了此操作方式的轉變。根據First Advantage於2024年8月發布的《2024年度趨勢報告》，過去兩年中，基於口腔液的篩檢使用量成長了74%，凸顯了檢測方法結構向著既能確保安全又不懲罰非工作時間行為的轉變。

同時，越來越多的機構將Fentanyl納入其標準藥物檢測項目，以填補傳統檢測方法在合成鴉片類藥物檢測方面的空白。這項擴展至關重要，因為員工在入職前檢測中可能呈現陰性，但在工作期間仍可能使用這些物質。檢測率的差異凸顯了廣泛篩檢的迫切性。根據Quest Diagnostics於2025年9月發布的《2025年藥物檢測指數》，隨機職場藥物檢測中Fentanyl的陽性率比入職前檢測高出707%。這項數據推動了市場對能夠識別傳統通訊協定遺漏的強效合成化合物的綜合檢測項目的需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球雇主與職場藥物檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（入職前藥物檢測/入職後檢測）
    • 依產品分類（耗材、設備、快速檢測設備、服務）
    • 依檢測方式（尿液、毛髮、口腔液、即時檢測）
    • 依藥物類型（酒精、大麻/毒品、古柯鹼、鴉片類藥物、安非他命/甲基安非他命、LSD、其他）
    • 依最終用途（IT/金融、製造業、運輸業、建築業、零售/旅館業、醫療保健業、教育業、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美雇主和職場藥物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲雇主和職場藥物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區雇主和職場藥物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲雇主及職場藥物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲雇主和職場藥物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球雇主與職場藥物檢測市場：SWOT 分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • First Advantage Corporation
  • Laboratory Corporation of America Holdings
  • Dragerwerk AG & Co. KGaA
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories, Inc.
  • Clinical Reference Laboratory Inc.
  • Quest Diagnostics Inc.
  • DISA Global Solutions Inc.
  • HireRight, LLC
  • OraSure Technologies Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27338

The Global Employer And Workplace Drug Testing Market is projected to expand from a valuation of USD 6.36 Billion in 2025 to USD 8.41 Billion by 2031, reflecting a compound annual growth rate of 4.77%. This market sector encompasses the laboratory services and diagnostic products used by organizations to screen their workforce for illicit substance use or medication misuse. The market's growth is fundamentally anchored by strict government safety mandates in high-risk industries and a corporate commitment to minimizing liabilities associated with workplace accidents and productivity losses. These drivers arise from core operational risk management and legal compliance necessities rather than the mere adoption of new collection technologies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.36 Billion
Market Size 2031USD 8.41 Billion
CAGR 2026-20314.77%
Fastest Growing SegmentTransportation
Largest MarketNorth America

However, the expansion of the market faces a significant hurdle due to the growing complexity of cannabis legislation, which creates compliance difficulties for employers dealing with contradictory state and federal laws. This regulatory fragmentation hampers the implementation of standardized testing protocols and generates uncertainty regarding the enforcement of impairment standards. Data from the American Trucking Associations indicates that in 2024, marijuana was responsible for nearly 60% of all positive drug tests among commercial drivers, underscoring the severe challenges organizations encounter in maintaining safety protocols within this shifting legal environment.

Market Driver

Strict government mandates and regulatory compliance, alongside the urgent need for workplace safety, serve as the primary catalysts for the Global Employer And Workplace Drug Testing Market. In high-stakes sectors such as logistics and manufacturing, employers are legally obligated to enforce rigorous screening measures to prevent accidents and reduce corporate liability. This operational necessity is intensifying as safety incidents involving impairment remain a persistent threat. According to the '2025 Drug Testing Index' by Quest Diagnostics, released in September 2025, the positivity rate for post-accident drug tests in the U.S. workforce hit 10.2% in 2024, highlighting the crucial role of testing in identifying hazards following safety failures. These mandates ensure a consistent baseline of market demand that remains resilient against economic fluctuations.

Simultaneously, the market is propelled by the rising global prevalence of illicit substance use and opioid addiction, which necessitates more comprehensive and frequent screening protocols. As drug consumption increases worldwide, the risk of employee impairment rises, compelling organizations to adopt thorough testing to safeguard productivity and workforce health. The UNODC's 'World Drug Report 2024', published in June 2024, reveals that the number of people using illicit drugs globally climbed to 292 million in 2022, a 20% increase over the previous decade. The severity of this issue is further illustrated by workplace medical emergencies; according to the National Safety Council in 2025, Emergency Medical Services were activated over 12,600 times in 2024 to respond to potential opioid overdoses in workplace settings.

Market Challenge

The escalating complexity of cannabis legislation presents a formidable barrier to the growth of the Global Employer and Workplace Drug Testing Market. With states legalizing marijuana for medical and recreational use while it remains federally illegal, employers face a conflicting maze of compliance requirements. This regulatory fragmentation creates significant legal liability and uncertainty regarding impairment enforcement, particularly for non-regulated roles. Consequently, organizations are becoming risk-averse, often choosing to scale back their screening protocols or eliminate marijuana testing entirely to avoid potential lawsuits, which directly reduces test volumes and limits the adoption of diagnostic services.

The market impact of this hesitancy is evident in recent industry data showing restricted comprehensive adoption. According to the Society for Human Resource Management, in 2024, only 40% of employers reported conducting drug testing for both regulated and non-regulated roles. This figure indicates that a substantial segment of the corporate landscape is refraining from implementing full-scale screening programs. The inability to establish standardized testing policies due to legislative confusion effectively limits the market's addressable customer base and hampers revenue growth.

Market Trends

The market is being reshaped by the widespread adoption of lab-based and rapid oral fluid testing, driven by Department of Transportation approval and the necessity to detect recent use. This method mitigates the risk of specimen adulteration common in urine testing by utilizing fully observed, non-invasive collections. Employers in safety-sensitive sectors are increasingly favoring this modality to distinguish active impairment from historical cannabis use, a capability that is crucial in legalized jurisdictions. This operational shift is quantified by significant volume growth; according to First Advantage's '2024 Annual Trends Report' from August 2024, the utilization of oral fluid-based screens grew by 74% over the preceding two years, highlighting a structural pivot toward testing methods that enforce safety without penalizing off-duty conduct.

Concurrently, organizations are expanding standard drug panels to include fentanyl, addressing the gap where legacy screens fail to detect synthetic opioids. This expansion is critical as employees may pass pre-employment checks while using these substances on the job. The urgency for broader screening is highlighted by disparities in detection rates; according to Quest Diagnostics' '2025 Drug Testing Index' from September 2025, the positivity rate for fentanyl in random workforce drug tests was 707% higher than in pre-employment tests. This statistic drives the market demand for comprehensive panels capable of identifying potent synthetic compounds missed by traditional protocols.

Key Market Players

  • First Advantage Corporation
  • Laboratory Corporation of America Holdings
  • Dragerwerk AG & Co. KGaA
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories, Inc.
  • Clinical Reference Laboratory Inc.
  • Quest Diagnostics Inc.
  • DISA Global Solutions Inc.
  • HireRight, LLC
  • OraSure Technologies Inc

Report Scope

In this report, the Global Employer And Workplace Drug Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Employer And Workplace Drug Testing Market, By Type

  • Pre-employment Drug Screens and Post-employment

Employer And Workplace Drug Testing Market, By Product

  • Consumables
  • Instruments
  • Rapid Testing Devices
  • and Services

Employer And Workplace Drug Testing Market, By Mode

  • Urine
  • Hair
  • Oral Fluid
  • and Instant Testing

Employer And Workplace Drug Testing Market, By Drug

  • Alcohol
  • Cannabis/Marijuana
  • Cocaine
  • Opioids
  • Amphetamine & Methamphetamine
  • LSD
  • and Others

Employer And Workplace Drug Testing Market, By End Use

  • IT/Finance
  • Manufacturing
  • Transportation
  • Construction
  • Retail & Hospitality
  • Healthcare
  • Education
  • Others

Employer And Workplace Drug Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Employer And Workplace Drug Testing Market.

Available Customizations:

Global Employer And Workplace Drug Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Employer And Workplace Drug Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Pre-employment Drug Screens and Post-employment)
    • 5.2.2. By Product (Consumables, Instruments, Rapid Testing Devices, and Services)
    • 5.2.3. By Mode (Urine, Hair, Oral Fluid, and Instant Testing)
    • 5.2.4. By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, and Others)
    • 5.2.5. By End Use (IT/Finance, Manufacturing, Transportation, Construction, Retail & Hospitality, Healthcare, Education, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Employer And Workplace Drug Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Mode
    • 6.2.4. By Drug
    • 6.2.5. By End Use
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Employer And Workplace Drug Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Mode
        • 6.3.1.2.4. By Drug
        • 6.3.1.2.5. By End Use
    • 6.3.2. Canada Employer And Workplace Drug Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Mode
        • 6.3.2.2.4. By Drug
        • 6.3.2.2.5. By End Use
    • 6.3.3. Mexico Employer And Workplace Drug Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Mode
        • 6.3.3.2.4. By Drug
        • 6.3.3.2.5. By End Use

7. Europe Employer And Workplace Drug Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Mode
    • 7.2.4. By Drug
    • 7.2.5. By End Use
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Employer And Workplace Drug Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Mode
        • 7.3.1.2.4. By Drug
        • 7.3.1.2.5. By End Use
    • 7.3.2. France Employer And Workplace Drug Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Mode
        • 7.3.2.2.4. By Drug
        • 7.3.2.2.5. By End Use
    • 7.3.3. United Kingdom Employer And Workplace Drug Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Mode
        • 7.3.3.2.4. By Drug
        • 7.3.3.2.5. By End Use
    • 7.3.4. Italy Employer And Workplace Drug Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Mode
        • 7.3.4.2.4. By Drug
        • 7.3.4.2.5. By End Use
    • 7.3.5. Spain Employer And Workplace Drug Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Mode
        • 7.3.5.2.4. By Drug
        • 7.3.5.2.5. By End Use

8. Asia Pacific Employer And Workplace Drug Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Mode
    • 8.2.4. By Drug
    • 8.2.5. By End Use
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Employer And Workplace Drug Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Mode
        • 8.3.1.2.4. By Drug
        • 8.3.1.2.5. By End Use
    • 8.3.2. India Employer And Workplace Drug Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Mode
        • 8.3.2.2.4. By Drug
        • 8.3.2.2.5. By End Use
    • 8.3.3. Japan Employer And Workplace Drug Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Mode
        • 8.3.3.2.4. By Drug
        • 8.3.3.2.5. By End Use
    • 8.3.4. South Korea Employer And Workplace Drug Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Mode
        • 8.3.4.2.4. By Drug
        • 8.3.4.2.5. By End Use
    • 8.3.5. Australia Employer And Workplace Drug Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Mode
        • 8.3.5.2.4. By Drug
        • 8.3.5.2.5. By End Use

9. Middle East & Africa Employer And Workplace Drug Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Mode
    • 9.2.4. By Drug
    • 9.2.5. By End Use
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Employer And Workplace Drug Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Mode
        • 9.3.1.2.4. By Drug
        • 9.3.1.2.5. By End Use
    • 9.3.2. UAE Employer And Workplace Drug Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Mode
        • 9.3.2.2.4. By Drug
        • 9.3.2.2.5. By End Use
    • 9.3.3. South Africa Employer And Workplace Drug Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Mode
        • 9.3.3.2.4. By Drug
        • 9.3.3.2.5. By End Use

10. South America Employer And Workplace Drug Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Mode
    • 10.2.4. By Drug
    • 10.2.5. By End Use
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Employer And Workplace Drug Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Mode
        • 10.3.1.2.4. By Drug
        • 10.3.1.2.5. By End Use
    • 10.3.2. Colombia Employer And Workplace Drug Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Mode
        • 10.3.2.2.4. By Drug
        • 10.3.2.2.5. By End Use
    • 10.3.3. Argentina Employer And Workplace Drug Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Mode
        • 10.3.3.2.4. By Drug
        • 10.3.3.2.5. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Employer And Workplace Drug Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. First Advantage Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Laboratory Corporation of America Holdings
  • 15.3. Dragerwerk AG & Co. KGaA
  • 15.4. Bio-Rad Laboratories, Inc.
  • 15.5. Abbott Laboratories, Inc.
  • 15.6. Clinical Reference Laboratory Inc.
  • 15.7. Quest Diagnostics Inc.
  • 15.8. DISA Global Solutions Inc.
  • 15.9. HireRight, LLC
  • 15.10. OraSure Technologies Inc

16. Strategic Recommendations

17. About Us & Disclaimer